These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29165546)

  • 21. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.
    Nicolazzo C; Raimondi C; Mancini M; Caponnetto S; Gradilone A; Gandini O; Mastromartino M; Del Bene G; Prete A; Longo F; Cortesi E; Gazzaniga P
    Sci Rep; 2016 Aug; 6():31726. PubMed ID: 27553175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pseudoprogression and Immune-Related Response in Solid Tumors.
    Chiou VL; Burotto M
    J Clin Oncol; 2015 Nov; 33(31):3541-3. PubMed ID: 26261262
    [No Abstract]   [Full Text] [Related]  

  • 23. Liquid Biopsy and Lung Cancer.
    Pisapia P; Malapelle U; Troncone G
    Acta Cytol; 2019; 63(6):489-496. PubMed ID: 30566947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lung cancer: Squiring immunotherapy to CheckMate.
    Hutchinson L
    Nat Rev Clin Oncol; 2015 Aug; 12(8):436. PubMed ID: 26122186
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.
    Ilie M; Long-Mira E; Bence C; Butori C; Lassalle S; Bouhlel L; Fazzalari L; Zahaf K; Lalvée S; Washetine K; Mouroux J; Vénissac N; Poudenx M; Otto J; Sabourin JC; Marquette CH; Hofman V; Hofman P
    Ann Oncol; 2016 Jan; 27(1):147-53. PubMed ID: 26483045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lung cancer: Liquid biopsy of SCLC chemosensitivity.
    Killock D
    Nat Rev Clin Oncol; 2017 Jan; 14(1):2. PubMed ID: 27922046
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunotherapy: pembrolizumab-is the writing on the wall for cancer?
    Hutchinson L
    Nat Rev Clin Oncol; 2015 Jul; 12(7):371. PubMed ID: 25963092
    [No Abstract]   [Full Text] [Related]  

  • 28. Possible applications of circulating tumor cells in patients with non small cell lung cancer.
    Tartarone A; Rossi E; Lerose R; Mambella G; Calderone G; Zamarchi R; Aieta M
    Lung Cancer; 2017 May; 107():59-64. PubMed ID: 27339469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
    Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
    J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KEYNOTE-024: Unlocking a pathway to lung cancer cure?
    Rusch VW; Chaft J; Hellmann M
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1777-1780. PubMed ID: 29395215
    [No Abstract]   [Full Text] [Related]  

  • 31. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
    Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in non-small-cell lung cancer treatment. Strategies include repeat biopsies and counting circulating cells.
    Duke Med Health News; 2011 Jun; 17(6):7. PubMed ID: 21710702
    [No Abstract]   [Full Text] [Related]  

  • 33. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
    Lupo A; Alifano M; Wislez M; Boulle G; Velut Y; Biton J; Cremer I; Goldwasser F; Leroy K; Damotte D
    Rev Pneumol Clin; 2018 Oct; 74(5):339-350. PubMed ID: 30337201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A banner year for immunotherapy and targeted therapy.
    Carlisle JW; Ramalingam SS
    Nat Rev Clin Oncol; 2019 Feb; 16(2):79-80. PubMed ID: 30538305
    [No Abstract]   [Full Text] [Related]  

  • 35. Single tube liquid biopsy for advanced non-small cell lung cancer.
    de Wit S; Rossi E; Weber S; Tamminga M; Manicone M; Swennenhuis JF; Groothuis-Oudshoorn CGM; Vidotto R; Facchinetti A; Zeune LL; Schuuring E; Zamarchi R; Hiltermann TJN; Speicher MR; Heitzer E; Terstappen LWMM; Groen HJM
    Int J Cancer; 2019 Jun; 144(12):3127-3137. PubMed ID: 30536653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in evidence-based medicine for immunotherapy of non-small cell lung cancer.
    Dong J; Li B; Zhou Q; Huang D
    J Evid Based Med; 2018 Nov; 11(4):278-287. PubMed ID: 30444051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents.
    Puri S; Chatwal M; Gray JE
    Expert Rev Respir Med; 2017 Oct; 11(10):791-805. PubMed ID: 28786318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liquid biopsies to optimize therapeutic efficacy in unresponsive lung cancer patients.
    Santarpia M; Funel N; Ali A; Giovannetti E
    Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):761-763. PubMed ID: 29933706
    [No Abstract]   [Full Text] [Related]  

  • 40. Role of liquid biopsies in colorectal cancer.
    Wills B; Gorse E; Lee V
    Curr Probl Cancer; 2018 Nov; 42(6):593-600. PubMed ID: 30268335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.